|
Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - HERON |
|
Research Funding - AstraZeneca; Pfizer |
|
|
Research Funding - Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; MedImmune; Merck; Onyx; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Patents, Royalties, Other Intellectual Property - GTx; GTx (I) |
|
|
|
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - BTG; Genentech/Roche; Merrimack; Merrimack |
Research Funding - AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Novartis (Inst); Pfizer (Inst); PPD (Inst); Taiho Pharmaceutical (Inst) |